Head-to-head · WeighScore
NuBloom vs Omada Health
The verdict
NuBloom takes it — 69/100 to 55.6/100.
NuBloom grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. NuBloom is a women's metabolic-health telehealth practice founded by family and integrative-medicine physician Dr.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | NuBloom | Omada Health |
|---|---|---|
| WeighScore | 69/100 | 55.6/100 |
| Grade | C | C |
| Scorecard rank | #137 | #436 |
| Semaglutide | $149/mo (2.4 mg dose, compounded) | Not disclosed |
| Tirzepatide | $279/mo (15 mg dose, compounded) | Not disclosed |
| Coverage | 49 states | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #137 · C
Strengths
- Transparent, openly published pricing: compounded semaglutide $149/mo and tirzepatide $279/mo as flexible month-to-month subscriptions
- Founded and medically led by a named physician (Dr. Marianne Pinkston Mueller, family/integrative medicine, 25+ years)
- Whole-person model pairs GLP-1s with hormone, gut-health and longevity care plus in-depth lab testing
- State coverage published openly: 49 states listed on the site (all except Mississippi)
- Optional 90-day 1:1 coaching program with weekly meetings and unlimited text support ($599/mo)
Where it loses points
- Compounding pharmacy partners are not named anywhere on the site — a transparency gap
- NuBloom's own LegitScript/PCAB status is not displayed; only its telehealth partner is certified
- Compounded medications are not FDA-approved; one FAQ loosely calls them 'FDA-approved,' contradicting the product pages
- All sales are final and medical consult fees are non-refundable; no returns on prescription products
- Disputes go to binding individual arbitration; the Terms' governing-law state is left as an unfilled '[STATE]' placeholder
Graded #436 · C
Strengths
- Added GLP-1 prescribing and medication management in late 2025
- Clinicians trained in obesity care, available in all 50 states
- Behavioral support wrapped before, during and after treatment
- GLP-1 Flex Care adds a cash-pay medication pathway in 2026
- Publicly traded, evidence-based virtual care platform
Where it loses points
- Core program distributed via employers and health plans, limited cash-pay
- GLP-1 prescribing is a recent addition still scaling
- GLP-1 Flex Care only rolling out to employers later in 2026
- No transparent published price for the core member program
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.